A Phase 2 interventional study of LUM001 (Maralixibat) and Placebo in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 9 sites in 6 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2021-07-14.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is one of 3 that started in 2014, is one of 6 in phase 2, and was the 6th registered.
31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.
Browse Alagille Syndrome studies →2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in Belgium, France, Germany and 5 more countries
Ages 2 mo+
Mirum Pharmaceuticals, Inc. · Sites in United States
By country, each count listing its studies:
Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 12 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2014.
This study's enrollment of 31 is close to the median of 31 across 15 interventional studies indexed under Alagille Syndrome.
Median enrollment 31 across the 7 interventional studies, 47 across the 2 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period in children with Alagille Syndrome (ALGS) designed to evaluate the safety and efficacy of LUM001 (Also known as maralixibat or MRX).
The study is divided into 6 parts: a 6-week open-label, dose escalation period, a 12-week open-label stable dosing period, a 4-week randomized, double-blind, placebo-controlled drug withdrawal period, a 26-week long-term stable dosing period, and an a 52-week optional follow-up treatment period, and a long-term optional follow-up treatment period for eligible participants who choose to stay on treatment with LUM001.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of cholestasis (one or more of the following):
Inclusion Criteria for participants to be eligible for the 52-week optional follow-up treatment period:
Inclusion Criteria for participants with LUM001dosing interruption \<7 days, or >=7 days:
Exclusion Criteria:
Exclusion Criteria for participants with LUM001 dosing interruption >=7 days:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid \[sBA\] level and ItchRO\[Obs\] score) and safety assessment. Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat.
Drug: LUM001 (Maralixibat)
Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)
Drug: Placebo
LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
Placebo will be administered orally once daily during randomized withdrawal period
Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18
The primary efficacy endpoint of this study was the mean change from Week 18 to Week 22 (the RWD period) of fasting sBA levels in participants who had a reduction in sBA ≥50% from baseline to Week 12 or Week 18 (Modified Intent-to-Treat \[MITT\] Population). Five participants in the MRX group and 10 participants in the placebo group met the prespecified sBA reduction criteria.
Time frame: Week 18 to Week 22
Change From Baseline to Week 18 in Fasting sBA Levels
This secondary efficacy endpoint is the mean change from baseline to Week 18 in fasting sBA levels
Time frame: Baseline to Week 18
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Obs)
This secondary efficacy endpoint is the change from baseline to Week 18 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
Time frame: Baseline to Week 18
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Pt)
This secondary efficacy endpoint is the change from baseline to Week 18 in pruritus as measured by ItchRO(Pt) weekly average morning score
Time frame: Baseline to Week 18
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Obs)
This secondary efficacy endpoint is the change from Week 18 to Week 22 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
Time frame: Week 18 to Week 22
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Pt)
This secondary efficacy endpoint is the change from Week 18 to Week 22 in pruritus as measured by ItchRO(Pt) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
Time frame: Week 18 to Week 22
Change From Baseline to Week 18 in Alkaline Phosphatase
This secondary efficacy endpoint is the mean change from baseline to Week 18 in ALP
Time frame: Baseline to Week 18
Change From Week 18 to Week 22 in Alkaline Phosphatase
This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in ALP
Time frame: Week 18 to Week 22
Change From Baseline to Week 18 in Alanine Aminotransferase
This secondary efficacy endpoint is the mean change from baseline to Week 18 in ALT
Time frame: Baseline to Week 18
Change From Week 18 to Week 22 in Alanine Aminotransferase
This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in alanine aminotransferase (ALT)
Time frame: Week 18 to Week 22
Change From Baseline to Week 18 in Total Bilirubin
This secondary efficacy endpoint is the mean change from baseline to Week 18 in total bilirubin
Time frame: Baseline to Week 18
Change From Week 18 to Week 22 in Total Bilirubin
This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in total bilirubin
Time frame: Week 18 to Week 22
Change From Baseline to Week 18 in Direct Bilirubin
This secondary efficacy endpoint is the mean change from baseline to Week 18 in direct bilirubin
Time frame: Baseline to Week 18
Change From Week 18 to Week 22 in Direct Bilirubin
This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in direct bilirubin
Time frame: Week 18 to Week 22
The participants were enrolled at 9 sites in 6 countries (Australia, UK, France, Poland, Spain and Belgium) between 28 October 2014 and 11 September 2015
| Milestone | Open-label Period: Maralixibat (LUM001) | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo | After Randomized Withdrawal Period: Maralixibat | Long-term Extension Period: Maralixibat |
|---|---|---|---|---|---|
| Started | 31 | 0 | 0 | 0 | 0 |
| Completed | 29 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 |
| Milestone | Open-label Period: Maralixibat (LUM001) | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo | After Randomized Withdrawal Period: Maralixibat | Long-term Extension Period: Maralixibat |
|---|---|---|---|---|---|
| Started | 0 | 13 | 16 | 0 | 0 |
| Completed | 0 | 13 | 16 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Open-label Period: Maralixibat (LUM001) | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo | After Randomized Withdrawal Period: Maralixibat | Long-term Extension Period: Maralixibat |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 29 | 0 |
| Completed | 0 | 0 | 0 | 23 | 0 |
| Not completed | 0 | 0 | 0 | 6 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Did not consent to protocol amendment for long term extension | 0 | 0 | 0 | 5 | 0 |
| Milestone | Open-label Period: Maralixibat (LUM001) | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo | After Randomized Withdrawal Period: Maralixibat | Long-term Extension Period: Maralixibat |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 23 |
| Completed | 0 | 0 | 0 | 0 | 14 |
| Not completed | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Did not consent to protocol amendment | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by caregiver | 0 | 0 | 0 | 0 | 1 |
The primary efficacy endpoint of this study was the mean change from Week 18 to Week 22 (the RWD period) of fasting sBA levels in participants who had a reduction in sBA ≥50% from baseline to Week 12 or Week 18 (Modified Intent-to-Treat \[MITT\] Population). Five participants in the MRX group and 10 participants in the placebo group met the prespecified sBA reduction criteria.
| μmol/L | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo |
|---|---|---|
| Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18 | -21.73 ± 43.125 | 95.55 ± 30.488 |
This secondary efficacy endpoint is the mean change from baseline to Week 18 in fasting sBA levels
| μmol/L | Open-label Period: MRX Baseline | Open-label Period: MRX Week 18 |
|---|---|---|
| Change From Baseline to Week 18 in Fasting sBA Levels | 283.43 ± 210.569 | 192.50 ± 161.278 |
This secondary efficacy endpoint is the change from baseline to Week 18 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
| Points | Open-label Period: MRX Baseline | Open-label Period: MRX Week 18 |
|---|---|---|
| Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Obs) | 2.909 ± 0.5480 | 1.203 ± 0.8446 |
This secondary efficacy endpoint is the change from baseline to Week 18 in pruritus as measured by ItchRO(Pt) weekly average morning score
| Points | Open-label Period: MRX Baseline | Open-label Period: MRX Week 18 |
|---|---|---|
| Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Pt) | 2.903 ± 0.6616 | 0.831 ± 0.8122 |
This secondary efficacy endpoint is the change from Week 18 to Week 22 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
| Points | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo |
|---|---|---|
| Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Obs) | 0.217 ± 0.2345 | 1.700 ± 0.2031 |
This secondary efficacy endpoint is the change from Week 18 to Week 22 in pruritus as measured by ItchRO(Pt) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).
| Points | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo |
|---|---|---|
| Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Pt) | -0.149 ± 0.3719 | 1.839 ± 0.2771 |
This secondary efficacy endpoint is the mean change from baseline to Week 18 in ALP
| U/L | Open-label Period: MRX Baseline | Open-label Period: MRX Week 18 |
|---|---|---|
| Change From Baseline to Week 18 in Alkaline Phosphatase | 601.3 ± 274.77 | 580.8 ± 215.50 |
This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in ALP
| U/L | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo |
|---|---|---|
| Change From Week 18 to Week 22 in Alkaline Phosphatase | 2.8 ± 22.55 | -7.2 ± 20.31 |
This secondary efficacy endpoint is the mean change from baseline to Week 18 in ALT
| U/L | Open-label Period: MRX Baseline | Open-label Period: MRX Week 18 |
|---|---|---|
| Change From Baseline to Week 18 in Alanine Aminotransferase | 181.0 ± 108.56 | 177.4 ± 92.08 |
This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in alanine aminotransferase (ALT)
| U/L | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo |
|---|---|---|
| Change From Week 18 to Week 22 in Alanine Aminotransferase | 34.5 ± 14.04 | 19.4 ± 12.56 |
This secondary efficacy endpoint is the mean change from baseline to Week 18 in total bilirubin
| mg/dL | Open-label Period: MRX Baseline | Open-label Period: MRX Week 18 |
|---|---|---|
| Change From Baseline to Week 18 in Total Bilirubin | 6.09 ± 5.781 | 5.12 ± 5.337 |
This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in total bilirubin
| mg/dL | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo |
|---|---|---|
| Change From Week 18 to Week 22 in Total Bilirubin | 0.32 ± 0.265 | 0.46 ± 0.238 |
This secondary efficacy endpoint is the mean change from baseline to Week 18 in direct bilirubin
| mg/dL | Open-label Period: MRX Baseline | Open-label Period: MRX Week 18 |
|---|---|---|
| Change From Baseline to Week 18 in Direct Bilirubin | 4.57 ± 3.666 | 3.98 ± 3.369 |
This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in direct bilirubin
| mg/dL | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo |
|---|---|---|
| Change From Week 18 to Week 22 in Direct Bilirubin | 0.13 ± 0.195 | 0.14 ± 0.174 |
Collected over Baseline to study completion (median of 2 years). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Period: Maralixibat (LUM001) | 0/31 (0%) | 4/31 (12.9%) | 29/31 (93.5%) |
| Randomized Withdrawal Period: MRX | 0/13 (0%) | 1/13 (7.7%) | 7/13 (53.8%) |
| Randomized Withdrawal Period: Placebo | 0/16 (0%) | 1/16 (6.3%) | 12/16 (75%) |
| After Randomized Withdrawal Period: Maralixibat | 0/29 (0%) | 5/29 (17.2%) | 25/29 (86.2%) |
| Long-term Extension Period: Maralixibat | 0/23 (0%) | 6/23 (26.1%) | 23/23 (100%) |
| Safety Population | 0/31 (0%) | 13/31 (41.9%) | 31/31 (100%) |
| Event | Open-label Period: Maralixibat (LUM001) | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo | After Randomized Withdrawal Period: Maralixibat | Long-term Extension Period: Maralixibat | Safety Population |
|---|---|---|---|---|---|---|
| Viral infectionInfections and infestations | 0/31 | 1/13 | 0/16 | 0/29 | 0/23 | 1/31 |
| PyrexiaGeneral disorders | 0/31 | 0/13 | 1/16 | 0/29 | 1/23 | 2/31 |
| Shock haemorrhagicVascular disorders | 0/31 | 0/13 | 1/16 | 0/29 | 0/23 | 1/31 |
| Multiple injuriesInjury, poisoning and procedural complications | 0/31 | 0/13 | 1/16 | 0/29 | 0/23 | 1/31 |
| Splenic ruptureInjury, poisoning and procedural complications | 0/31 | 0/13 | 1/16 | 0/29 | 0/23 | 1/31 |
| Chest painGeneral disorders | 0/31 | 0/13 | 1/16 | 0/29 | 0/23 | 1/31 |
| Forearm fractureInjury, poisoning and procedural complications | 0/31 | 0/13 | 0/16 | 0/29 | 1/23 | 1/31 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 0/31 | 0/13 | 0/16 | 1/29 | 1/23 | 1/31 |
| Marrow hyperplasiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/31 | 0/13 | 0/16 | 0/29 | 1/23 | 1/31 |
| Cardiac dysfunctionCardiac disorders | 0/31 | 0/13 | 0/16 | 0/29 | 1/23 | 1/31 |
| Event | Open-label Period: Maralixibat (LUM001) | Randomized Withdrawal Period: MRX | Randomized Withdrawal Period: Placebo | After Randomized Withdrawal Period: Maralixibat | Long-term Extension Period: Maralixibat | Safety Population |
|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 12/31 | 1/13 | 1/16 | 6/29 | 12/23 | 18/31 |
| DiarrhoeaGastrointestinal disorders | 13/31 | 1/13 | 1/16 | 5/29 | 7/23 | 18/31 |
| PyrexiaGeneral disorders | 6/31 | 0/13 | 1/16 | 7/29 | 10/23 | 17/31 |
| VomitingGastrointestinal disorders | 11/31 | 1/13 | 1/16 | 2/29 | 8/23 | 16/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/31 | 0/13 | 0/16 | 3/29 | 8/23 | 13/31 |
| NasopharyngitisInfections and infestations | 4/31 | 1/13 | 1/16 | 8/29 | 9/23 | 13/31 |
| PruritusSkin and subcutaneous tissue disorders | 3/31 | 1/13 | 5/16 | 2/29 | 0/23 | 9/31 |
| HeadacheNervous system disorders | 5/31 | 0/13 | 0/16 | 2/29 | 4/23 | 9/31 |
| Upper respiratory tract infectionInfections and infestations | 6/31 | 2/13 | 0/16 | 3/29 | 4/23 | 9/31 |
| Ear infectionInfections and infestations | 3/31 | 0/13 | 0/16 | 4/29 | 5/23 | 8/31 |
| Age, Continuous(years of age) | Open-label Period: Maralixibat |
|---|---|
| Mean | 5.4 ± 4.25 |
| Age, Customized(Participants) | Open-label Period: Maralixibat |
|---|---|
| <2 years | 6 |
| 2 to 4 years | 9 |
| 5 to 8 years | 9 |
| 9 to 12 years | 4 |
| 13 to 18 years | 3 |
| Sex: Female, Male(Participants) | Open-label Period: Maralixibat |
|---|---|
| Female | 12 |
| Male | 19 |
| Race (NIH/OMB)(Participants) | Open-label Period: Maralixibat |
|---|---|
| American Indian or Alaska Native | NA |
| Asian | NA |
| Native Hawaiian or Other Pacific Islander | NA |
| Black or African American | NA |
| White | NA |
| More than one race | NA |
| Unknown or Not Reported | NA |
| Region of Enrollment(participants) | Open-label Period: Maralixibat |
|---|---|
| Australia | 9 |
| Belgium | 5 |
| France | 9 |
| Poland | 3 |
| Spain | 2 |
| United Kingdom | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2014 to primary completion in May 2020, 67 months.
Results were first posted in Jul 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat